BofA/Merrill Lynch Downgrades Mindray Medical (MR) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MR Hot Sheet
Price: $5.36 --0%
Rating Summary:
6 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
6 Buy, 17 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
BofA/Merrill Lynch downgraded Mindray Medical (NYSE: MR) from Buy to Neutral.
For an analyst ratings summary and ratings history on Mindray Medical click here. For more ratings news on Mindray Medical click here.
Shares of Mindray Medical closed at $31.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Central Bancompany (CBC) to Neutral
- Empower Brands proposes to buy Helen of Troy for $37 a share
- JPMorgan Downgrades Fidelity National Information Services (FIS) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
